Issue Date: January 4, 2016
Gene Editing: Bayer and Crispr Therapeutics form CRISPR/Cas9 technology pact
Bayer and Crispr Therapeutics have established a joint venture to use CRISPR/Cas9 gene-editing technology to develop therapies to treat blood disorders, blindness, and congenital heart disease. Bayer will sink at least $300 million into R&D over the five-year pact and is taking a minority stake worth $35 million in CRISPR Therapeutics.
Like the “find and replace” function in Microsoft Word, the CRISPR/Cas9 system enables researchers to precisely snip out problematic stretches of DNA and swap . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society